NICE rejects Novartis migraine drug

Britain ' s National Institute for Health and Care Excellence (NICE) rejected Novartis ’s migraine drug, Aimovig, concluding that the drug was not a cost-effective use of resources.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news